United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Hsbc Holdings PLC

Hsbc Holdings PLC lowered its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 9.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 204,893 shares of the biotechnology company's stock after selling 20,349 shares during the quarter. Hsbc Holdings PLC owned 0.46% of United Therapeutics worth $72,358,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Newbridge Financial Services Group Inc. purchased a new position in United Therapeutics in the 4th quarter worth $25,000. Millstone Evans Group LLC acquired a new stake in shares of United Therapeutics in the fourth quarter valued at about $67,000. MassMutual Private Wealth & Trust FSB increased its stake in United Therapeutics by 31.9% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after buying an additional 58 shares in the last quarter. Natixis purchased a new position in shares of United Therapeutics in the fourth quarter valued at approximately $85,000. Finally, Anchor Investment Management LLC boosted its stake in shares of United Therapeutics by 12.0% in the fourth quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock worth $99,000 after acquiring an additional 30 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR traded up $5.66 during mid-day trading on Monday, reaching $297.04. 410,281 shares of the company's stock were exchanged, compared to its average volume of 447,897. The company's 50-day moving average is $308.67 and its 200-day moving average is $346.42. The firm has a market capitalization of $13.34 billion, a price-to-earnings ratio of 13.05, a PEG ratio of 0.97 and a beta of 0.63. United Therapeutics Co. has a 52-week low of $233.31 and a 52-week high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million. During the same period in the previous year, the firm earned $4.36 EPS. As a group, equities analysts predict that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

UTHR has been the subject of several recent research reports. StockNews.com raised United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday, April 17th. Bank of America raised shares of United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price target on the stock in a research note on Monday, April 21st. UBS Group boosted their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. HC Wainwright reiterated a "buy" rating and issued a $425.00 price objective on shares of United Therapeutics in a report on Thursday, February 27th. Finally, Wells Fargo & Company restated an "equal weight" rating and set a $314.00 target price (down from $395.00) on shares of United Therapeutics in a report on Friday. Four analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, United Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $390.17.

Insider Activity at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $371.05, for a total value of $3,710,500.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares in the company, valued at $956,195.85. The trade was a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction on Thursday, April 17th. The shares were sold at an average price of $283.78, for a total value of $3,121,580.00. Following the completion of the transaction, the executive vice president now owns 36,781 shares of the company's stock, valued at approximately $10,437,712.18. This trade represents a 23.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 74,500 shares of company stock worth $24,472,050 in the last three months. 11.90% of the stock is owned by company insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.